It is widely accepted that cytotoxic T and NK cells store effector proteins including granzymes, perforin and Fas ligand (FasL) in intracellular granules, often referred to as secretory lysosomes. Upon target cell encounter, these organelles are transported to the cytotoxic immunological synapse, where they fuse with the plasma membrane to release the soluble effector molecules and to expose transmembrane proteins including FasL on the cell surface. We previously described two distinct species of secretory vesicles in T and NK cells that differ in size, morphology and protein loading, most strikingly regarding FasL and granzyme B. We now show that the signal requirements for the mobilization of one or the other granule also differ substantially. We report that prestored FasL can be mobilized independent of extracellular Ca 2+ , whereas the surface exposure of lysosome-associated membrane proteins (Lamps; CD107a and CD63) and the release of granzyme B are calcium-dependent. The use of selective inhibitors of actin dynamics unequivocally points to different transport mechanisms for individual vesicles. While inhibitors of actin polymerization/ dynamics inhibit the surface appearance of prestored FasL, they increase the activation-induced mobilization of CD107a, CD63 and granzyme B. In contrast, inhibition of the actin-based motor protein myosin 2a facilitates FasL-, but impairs CD107a-, CD63-and granzyme B mobilization. From our data, we conclude that distinct cytotoxic effector granules are differentially regulated with respect to signaling requirements and transport mechanisms. We suggest that a T cell might 'sense' which effector proteins it needs to mobilize in a given context, thereby increasing efficacy while minimizing collateral damage.
Introduction
One of the major tasks of the immune system is the clearance of virus-infected or transformed cells to efficiently combat infections and to prevent cancer (1) . Also, the termination of immune responses is associated with the clearance of unneeded effector cells by activation-induced cell death (AICD) involving cytotoxic effector proteins [e.g. Fas ligand (FasL)]. Dysregulation of cell death-associated immune homeostasis might foster autoimmune phenomena or even account for hemophagocytic lymphohistiocytosis, a life-threatening condition characterized by an excessive inflammatory response and hypercytokinemia (2) . The removal of unwanted cells is performed by cytotoxic lymphocytes (CLs) with CD8 + αβ and γδ T cells and NK cells being the most prominent populations (1) . However, CD4 + T cells can also develop cytotoxic potential when activated and expanded in vitro or in vivo (3, 4) .
Upon encounter and recognition of a target cell, cytotoxic αβ and γδ T cells are activated by different MHC-dependent or -independent antigens via their respective TCRs. In contrast, NK cell activation is regulated through a multitude of germline-encoded receptors that for instance sense altered levels of MHC or of stress proteins. Although the triggers for distinct CLs vary substantially, evolution has selected a common arsenal of cytotoxic effectors for innate and adaptive CLs. In this scenario, the CL polarizes towards the target cell and individual surface proteins segregate into distinct membrane areas to form a characteristic cytotoxic immunological synapse (IS). The synapse composition assures a target-restricted action of the cytotoxic effector molecules (5, 6) . However, ISs are highly dynamic and versatile structures and the segregation of surface proteins into central and peripheral supramolecular activation clusters-a hallmark of the mature IS-might be dispensable for cell-mediated cytotoxicity (7).
Mechanistically, two major cytotoxic pathways for target cell destruction have been described (1) . First, CL activation induces the expression of the death factor FasL that effectively triggers target cell apoptosis via ligation of its widely expressed receptor Fas. Second, CLs store soluble cytotoxic effector proteins such as granzymes, perforin and others in specialized secretory granules. Upon target cell conjugation, these granules are transported to the site of intercellular contact where they fuse with the plasma membrane to release their content into the IS. According to the classical model, perforin then forms pores within the target cell membrane to allow granzymes to enter the cell. Subsequently, granzymemediated cleavage of substrates, including for example caspase-3 and Bid, ultimately causes target cell death by apoptosis (1, (8) (9) (10) .
However, the concept of two distinct pathways has been challenged by the finding that the FasL, presumably together with granzyme B and perforin, is also stored in lysosome-related intracellular granules and only becomes exposed on the cell membrane upon degranulation (11) . The compartment controlling cell-mediated cytotoxicity in T and NK cells was categorized as a T-and NK-cell-specific secretory lysosome (SL). SLs are dual-function organelles that combine the properties of conventional lysosomes [low pH, lysosomal hydrolases and membrane proteins such as CD107a/lysosome-associated membrane protein 1/Lamp1 and CD63] and secretory granules that store cell type-specific effector proteins and allow for their regulated release in response to appropriate stimuli (12, 13) . Since CD107a is abundantly expressed in the membrane of the SLs of CLs, degranulation is accompanied by CD107a mobilization to the cell surface. Therefore, quantification of cell surface CD107a is utilized as a measure for cytolytic activity of T and NK cells (14, 15) .
We previously described two distinct species of lysosomerelated secretory vesicles in T cells that contained either FasL or granzyme B. The isolated organelles did not only differ in morphology (size, electron density) and protein loading (e.g. regarding cytotoxic effector proteins) but also turned out to be associated with distinct cytoskeletal elements (16) (17) (18) . This in turn indicated potentially different mobilization mechanisms, similar to what had also been suggested earlier by the groups of Ostergaard and Brunner (see 'Discussion' for more details) (19) (20) (21) .
Using ionophores or calcium chelators, we show that in human T cells, Ca 2+ requirements for the mobilization of prestored FasL, CD107a, CD63 and granzyme B are substantially different. In parallel, stimulation triggers a Ca 2+ -dependent de novo synthesis of FasL and granzyme B resulting in a delayed phase of surface expression or release. Additional mechanistic information was obtained when we used a variety of inhibitors addressing different steps of actin cytoskeleton dynamics. Selective inhibition of one or the other pathway strongly supports the novel concept of different transport mechanisms for individual vesicles or effector proteins.
Taken together, these data indicate that non-transformed human T cells do not only possess at least two distinct species of lysosome-related cytotoxic effector vesicles, but that these individual effector vesicles or associated proteins might also be differentially regulated with respect to signaling requirements and mechanisms for their transport and mobilization. Adding this new level of complexity to the regulation of lymphocytemediated cytotoxicity, we suggest that a given T cell might in fact sense which arsenal of effector vesicles or proteins it needs to mobilize to kill a given target cell, thereby increasing specificity and efficacy while minimizing collateral damage.
Methods

Cells
The human T-cell clones/lines used in this study were established, maintained and propagated in this laboratory as described before and include the CD4 + αβ T-cell clones A37/10 (22), D894/25 (22, 23) , 12603 and 12632 (24) , the CD8 + αβ T-cell clone D904/4 (23) and the CD8 + αβ T-cell line KCD8 (24) . Briefly, clone cells were re-stimulated periodically using a feeder cocktail with irradiated EBV-transformed B lymphoblastoid cells and freshly prepared allogeneic PBMCs [isolated by Ficoll (#6115, Merck, Darmstadt, Germany) density gradient centrifugation from blood specimens of healthy donors provided by the Institute for Transfusion Medicine of the University Hospital Schleswig-Holstein Campus Kiel] in the presence of 0.5 µg ml −1 phytohemagglutinin A (PHA, #R30852801, Thermo Fisher Scientific, Waltham, MA, USA). After 3 days, dead cells were removed by Ficoll density centrifugation and T cells were further propagated in the presence of human rIL-2 (10 U ml −1 , Novartis, Basel, Switzerland). All T-cell lines and clones were kept in RPMI 1640 with 2 mM glutamine and 25 mM HEPES (#52400-025, Thermo Fisher Scientific), supplemented with 100 U ml −1 penicillin/100 µg ml −1 streptomycin (#15070063, Thermo Fisher Scientific) and 10% fetal calf serum (FCS, #10270-106, Thermo Fisher Scientific), and were used in the experiments on day 14-20 after re-stimulation. The phenotype of T-cell clones/lines was periodically checked by flow cytometry. Polyclonal T-cell blasts were generated by incubation of PBMCs (10 6 cells ml −1 in RPMI 1640 medium supplemented with 10% heat-inactivated FCS) with 0.5 µg ml −1 PHA. After 3-4 days of stimulation, dead cells were removed by Ficoll gradient centrifugation and T-cell blasts were expanded in RPMI medium 1640 with 10% FCS, antibiotics and rIL-2 at 37°C. All blood donors provided informed consent, and the study was approved by the Institutional Ethics Review Board of Kiel University Medical Faculty (D485/14).
T-cell stimulation
Cells (14-20 days after re-stimulation) were adjusted to 1 × 10 6 cells ml −1 and 180 µl of the cell suspension were transferred to 96-well flat bottom plates. TPA (12-O-tetradecanoylphorbol-13-acetate, also termed PMA, #P8139, Merck, f.c. 20 ng ml −1 ) and/or ionomycin (#407950, Merck, f.c. 500 ng ml −1 ) were
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added in an additional 20 µl to stimulate the cells for up to 3 h. At the end of the indicated incubation period, cells were transferred to a second 96-well V-bottom plate and subjected to immunofluorescence staining for flow cytometry. In addition, supernatants were harvested, cleared by centrifugation and stored at −20°C for further use.
Pre-incubation with the following inhibitors and reagents was performed for 30 min at 37°C: EGTA at 4 mM (#1084350025, Merck), MgCl 2 at 4 mM (#1058330250, Merck), Cycloheximide (CHX) at 1 µM (#C1988, Merck), Latrunculin A at 1 µg (#3973, Bio-Techne, Minneapolis, MN, USA) and Blebbistatin at 100 µM (#B0560, Merck).
Because of donor-dependent variations in the composition of PBMCs used for re-stimulation and/or different reactivities of individual clones and lines after re-stimulation and depending on the number of re-stimulations after thawing, we noted slight differences in the slope or amplitude of individual measurements. Therefore, we decided to only present representative individual experiments. Nonetheless, for statistical analysis, three to four single experiments were performed within 2-3 consecutive days in a given re-stimulation cycle.
Flow cytometry
Cells were centrifuged in 96-well V-bottom plates, washed and stained with the fluorophore-conjugated monoclonal antibodies (mabs). After incubation for 30 min on ice, the cells were washed twice, fixed in 1% paraformaldehyde and analyzed on a FACSCalibur flow cytometer using the CellQuest™ analysis software (BD-Biosciences, Franklin Lakes, NJ, USA The bright-field gradient root mean square (RMS) feature was used to gate on cells that were in focus. Bright-field area versus aspect ratio features were plotted and used to gate on single cells. Dead cells were excluded from the analysis based on the fluorescence intensity in channel 5. Cells with saturated pixels were excluded from the analysis by plotting the histogram for the saturation count feature (number of saturated pixels in each cell). Analyte positive cells were considered for colocalization analysis based on isotype staining and/or unstained controls. The Bright Detail Similarity (BDS) R3 feature was used to measure colocalization in double-positive cells only. The BDS score quantifies the degree of similarity between any two channel images on a pixel-by-pixel and cell-by-cell basis. The BDS is calculated in a three-step process including an initial imaging process to enhance bright details, the calculation of a nonmean normalized Pearson's correlation coefficient and a subsequent log transformation of the correlation. The BDS represents the mean of the resulting roughly Gaussian distributions with values <1.5 for poorly and >3 for well colocalized analytes (25) .
ELISA
Levels of granzyme B in cell-free supernatants were determined by a sandwich ELISA from Bio-Techne (#DY2906-05) following the manufacturer's instructions.
Results
Membrane and intracellular localization of FasL, CD107a, CD63 and granzyme B
Since the death-inducing receptor Fas is widely expressed on different cell types, the expression of its ligand, FasL (CD95L, CD178), is tightly controlled to prevent unwanted damage. Thus, on expanded T cells, hardly any FasL is detectable on the cell surface (Fig. 1) . Instead, FasL is stored in intracellular granules referred to as SLs (11, 26) and is thus detected only upon cell permeabilization. Conventional lysosomes as well as SLs are characterized by the presence of the transmembrane proteins CD63 and CD107a. Thus, the extent of CD107a surface expression is considered to correlate with degranulation events in the course of a cytotoxic response (14, 15) . Of note, both CD107a and CD63 are also constitutively expressed at the cell surface of activated and in vitro expanded T cells although the majority of both proteins is stored intracellularly. As expected, the soluble effector protein granzyme B is exclusively located intracellularly ( Fig. 1 ).
Differential mobilization of FasL, CD107a and CD63
Upon target cell encounter, SLs are transported to the site of cell-cell contact, where they fuse with the plasma membrane to release the soluble effector molecules into the IS and to expose FasL locally on the cell surface to induce target cell death. We previously described two distinct species of lysosome-related effector compartments in T cells that differ in several parameters including the abundance of cytotoxic effector proteins. In earlier experiments, it looked as if FasL and the Lamps CD107a (Lamp1) and CD63 (Lamp3) might be interconnected since they segregated to the same organelle fraction (17, 18, 27) . In order to address the inducible mobilization of the proteins to the cell surface, we first investigated whether CD107a and CD63 follow the same signal requirements for mobilization as the FasL. To test this, T-cell lines and clones representing different T-cell subpopulations were stimulated with phorbol ester (TPA) and calcium ionophore (ionomycin) alone or in combination. The kinetics of FasL, CD107a and CD63 surface expression were followed by flow cytometry for up to 3 h [ Fig (24, 28) , the TPA/ionomycin-induced FasL surface expression follows a biphasic expression pattern with a first maximum after 10 min representing the mobilization of prestored FasL molecules from intracellular vesicles ( Fig. 2A, triangles) . With ongoing stimulation, expression decreases resulting in a minimum after 40-60 min. After about 90-120 min, a second maximum becomes apparent. Previous analyses from our and other groups clearly attributed this late phase of surface expression to FasL de novo synthesis (20, 24) . Afterwards, FasL surface expression decreases to reach the baseline level after 3 h. Of note, also upon stimulation with phorbol ester alone ( Fig. 2A , diamonds), FasL is rapidly mobilized to the cell surface resulting in the first maximum after 10 min. However, after this first peak, FasL expression constantly decreases and no second increment is observed. Interestingly, when the cells are treated with ionomycin alone ( Fig. 2A, squares) , both phases of FasL expression are detectable, although the expression levels do not reach the same amplitude as in the presence of additional TPA. Especially the first phase is significantly less pronounced upon ionomycin-only stimulation. Of note, similar overall kinetics were observed for CD8 + T cells ( Fig. 2A ) and for cloned CD4 + T cells (Supplementary Figure 1A) . Performing several single experiments, we could also demonstrate that for a given T-cell clone/line, these alterations are highly reproducible and statistically significant (Fig. 2B) . Our results thus demonstrate that preformed FasL can also be mobilized in a PKC-dependent and calcium-independent manner. As described before (24, 28), we had observed similar overall kinetics for FasL surface expression with individual differences in slope and amplitude also in γδ T cells.
Since FasL was described to be stored in SLs that in turn are characterized by high abundance of Lamps, we analyzed the activation-induced mobilization of the two most prominent lysosomal marker proteins CD107a and CD63 in parallel. Upon stimulation with both TPA and ionomycin, CD107a surface expression is rapidly increased within only 10 min and reaches a maximum after 60 min (Fig. 2C, triangles) . With ongoing stimulation, however, CD107a surface expression remains at a high level throughout the analyzed time frame of 3 h. Employing ionomycin alone, CD107a surface expression also increases within 10 min, but remains stable at a considerably lower level compared to the induction with TPA/ 
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ionomycin (Fig. 2C, squares) . In striking contrast to FasL, TPA alone does not induce CD107a surface expression (Fig. 2C,  diamonds) . Again, these results proved to be significant (Fig. 2D ) and similar results (albeit with a more pronounced induction of CD107a by ionomycin alone) were seen for CD4 + T cells (Supplementary Figure 1B) . Of note, to follow the timedependent CD107a surface expression, we refrained from classical degranulation assays that are performed in the presence of an excess of staining antibody and CHX during stimulation and thus omit the detection of possible reinternalization events and of newly synthesized protein. Similar to CD107a, surface expression of CD63 constantly increases upon stimulation with TPA/ionomycin ( Fig. 2E, triangles;  Supplementary Figure 1C) . Ionomycin also induces CD63 surface appearance, albeit at lower levels and especially at later time points. Also in the case of CD63, stimulation with TPA alone is not sufficient to mobilize the protein ( Fig. 2E and  F; Supplementary Figure 1C) . Importantly, as documented in Supplementary Figure 2 , we always observed the increase of FasL, CD107a and CD63 expression in the whole population and not only a fraction of cells.
Since we initially expected that the observed association of FasL with CD107a and CD63 with a common vesicular compartment would result in a parallel increase or kinetics of activation-induced expression, the differential kinetics observed in all experiments with different T-cell clones was quite unexpected. In addition, the results clearly indicated that-in stark contrast to what we observed for FasL-the rapid mobilization of both CD107a and CD63 is primarily calcium-dependent, although full degranulation might require additional PKC activation.
To further prove that signal requirements for the mobilization of FasL and of CD107a or CD63 in fact differ with regard to the availability of calcium ions, we tested the effect of the Ca 2+ chelator EGTA on the activation-induced surface expression (Fig. 3) . As shown in previous experiments, the stimulation of T cells with phorbol ester alone is sufficient to induce the early phase of FasL surface expression, whereas de novo synthesis is not induced and thus no late phase of surface expression is observed. The presence of EGTA has hardly any effect on the observed kinetics, once again highlighting that the first phase of FasL expression is indeed calcium-independent ( and B). In line with these results, treatment with TPA and ionomycin induces both the early expression of preformed FasL and a later phase of surface expression of newly synthesized FasL. Only this second phase of FasL expression is significantly affected by the presence of EGTA (Fig. 3I and  J) . Again, treatment with ionomycin alone induces only very minor early and some late FasL expression which is, however, abrogated by Ca 2+ chelation (Fig. 3E and F) . In contrast, CD107a is not mobilized at all by TPA (Fig. 3C  and D) , while stimulation with both TPA and ionomycin leads to an immediate increase in CD107a surface expression that constantly increases over time. This TPA/ionomycin-induced expression is completely abolished in the presence of EGTA (Fig. 3K and L) . Again, ionomycin alone also induces a rapid increase of CD107a surface expression that is, however, less pronounced compared to TPA/ionomycin treatment, especially at later time points. Also this ionomycin-induced CD107a surface expression is completely inhibited in the presence of EGTA (Fig. 3G and H) .
Like in the case of CD107a, the ionomycin- (Fig. 4B ) and the TPA/ionomycin-induced (Fig. 4C ) mobilization of CD63 is almost completely abrogated in the presence of EGTA, whereas TPA stimulation alone does not induce an increase in CD63 surface expression (Fig. 4A) .
Mechanistic peculiarities of FasL, CD107a and CD63 mobilization
The biphasic expression pattern of FasL relies on the mobilization of preformed molecules in the first phase and on the trafficking of newly synthesized FasL to the cell surface in the second phase (24) . We were, therefore, keen to delineate whether CD107a and CD63 were also regulated in a similar manner. To distinguish between prestored molecules and newly synthesized proteins contributing to the activationinduced surface expression, protein translation was inhibited with CHX. We showed before that the first phase of FasL surface expression is hardly affected by CHX, whereas the second phase is more or less completely abrogated (24, 28) . Again, the analysis of TPA/ionomycin-induced FasL mobilization after 10 and 120 min representing early and late FasL surface appearance in the absence or presence of CHX demonstrates that initial mobilization relies on preformed molecules and late expression on a secondary supply of de novo synthesized FasL (Fig. 5A and B) .
Interestingly, as shown in Fig. 5C and D, CD107a surface expression is even more pronounced in the presence of CHX especially at later time points. This indicates that the control of CD107a translocation might employ additional mechanisms, possibly an activation-induced, de novo synthesized negative regulator. Nevertheless, the CD107a surface expression is not decreased in the presence of CHX, pointing towards a minor contribution of newly synthesized CD107a to the overall surface expression.
In line with this, the activation-induced surface expression of CD63 is also rather increased upon CHX-treatment (Fig. 6A) , even though this effect is less pronounced compared to CD107a. The kinetics suggest that the activationinduced CD107a/CD63 surface expression predominantly relies on the slow but constant release of preformed molecules with newly synthesized proteins only playing a minor role.
Up to this point, the presented results indicate that the mobilization mechanisms of FasL and CD107a and CD63 differ substantially. Whereas the activation-induced surface expression of CD107a and CD63 relies on a calcium-dependent continuous release of stored molecules, FasL surface expression reflects both a calcium-independent release of stored molecules and a calcium-dependent mobilization of newly synthesized protein. However, it is still not completely solved whether Ca 2+ is required for FasL gene transcription or for the transport of the newly synthesized FasL molecules.
In CLs, both the transport and release of secretory granules strictly depend on inducible alterations in cytoskeletal dynamics (29, 30) . Therefore, we next investigated whether and how inhibitors targeting the actin cytoskeleton would influence the activation-induced surface expression of CD107a and FasL. This approach might also clarify whether the mobilization of the two proteins indeed requires different cytoskeletal elements. To interfere with the reorganization of the actin cytoskeleton, we employed the inhibitor Latrunculin A. Latrunculin A binds to G-actin at a 1:1 stoichiometry, thereby preventing actin polymerization and thus leading to the disruption of actin filaments (31, 32) .
Interestingly, Latrunculin A inhibits the mobilization of preformed FasL ( Fig. 5E and F; Supplementary Figure 3A) , whereas it induces a rapid and virtually explosive increase of activation-induced CD107a surface expression ( Fig. 5G and  H; Supplementary Figure 3B) . Although Latrunculin A already slightly facilitated CD107a surface expression in unstimulated cells, this effect became most obvious upon stimulation. Of note, we occasionally observed a less pronounced inhibitory effect on the late phase of FasL mobilization ( Fig. 5F; Supplementary  Figure 3A) . Interestingly, Latrunculin A also facilitated CD63 mobilization, although surface expression was not affected after 10 min of stimulation or in unstimulated cells (Fig. 6B) .
Especially in NK cells, degranulation processes have been functionally associated with the actin motor protein myosin 2a (33) . Notably, we reported that myosin 2a is also associated with cytotoxic granules of human T cells (18) . Interestingly, the myosin 2 inhibitor Blebbistatin stabilizes FasL surface expression. This effect applies to the constitutive expression without stimulation as well as to both phases of induced surface exposure ( Fig. 5I and J) . The activationinduced mobilization of CD107a (Fig. 5K and L) and CD63 (Fig. 6C) , however, is rather impaired in the presence of Blebbistatin, indicating that myosins are also differentially involved in the mobilization of either FasL or CD107a. Of note, especially with respect to the activation-induced surface expression of CD107a, we observed major differences in maximal induction depending on both the cell line used ( Fig. 5D and H) and the re-stimulation cycle (Fig. 5D and L) .
Mobilization of granzyme B
Besides employing FasL as a death ligand, T-cell cytotoxicity might also employ the concerted action of soluble cytotoxic ) and ionomycin (500 ng ml effector molecules including granzymes and perforin (1) . Using the same cell culture strategy, we, therefore, addressed in parallel the release of granzyme B into the culture supernatants of differentially activated T cells. To this end, we collected culture supernatants to analyze the presence of granzyme B by ELISA ( Fig. 7; Supplementary Figure 3C) .
When T cells are stimulated with TPA and ionomycin, considerable amounts of granzyme B are detected in the supernatants after 120 min (Fig. 7C) . Granzyme B release in response to ionomycin alone seems less pronounced although still considerable (Fig. 7B) . Interestingly, we also observed some granzyme B release upon TPA stimulation (Fig. 7A) .
To further delineate the signaling requirements of granzyme B mobilization, we analyzed its activation-induced release in the presence of EGTA (Fig. 7A-C) . EGTA completely abrogates TPA/ionomycin- (Fig. 7C ) and ionomycin-induced (Fig. 7B) granzyme B release indicating that the mobilization strictly depends on Ca
2+
. Interestingly, TPA-induced granzyme B mobilization is not affected by the presence of EGTA (Fig. 7A) .
To get further insight into the mechanisms of granzyme B mobilization, we also investigated the effects of CHX, Latrunculin A and Blebbistatin. In contrast to CD107a, the inhibition of protein translation by CHX almost completely prevents the detection of granzyme B in respective culture supernatants (Fig. 7D) . As observed for CD107a and CD63, Latrunculin A facilitates the release of granzyme B ( Fig. 7E;  Supplementary Figure 3C ). This effect is already evident in unstimulated cells but much more pronounced upon stimulation. On the other hand, similar to what we observed for CD107a and CD63, Blebbistatin decreases activationinduced granzyme B mobilization (Fig. 7F) .
Subcellular localization of lysosomal marker and cytotoxic effector proteins
Given these remarkable differences in the mobilization of FasL and of CD107a/CD63/granzyme B, we analyzed the subcellular location of the endogenous proteins in human CD8 + T-cell blasts via imaging cytometry (Fig. 8A) and quantified the degree of colocalization employing the BDS feature (Fig. 8B) , which represents the log-transformed Pearson correlation of respective images on a pixel-by-pixel and cell-by-cell basis (25) 
Discussion
Although most textbooks still state that cytotoxicity of T and NK cells depends on the activation-induced mobilization of cytotoxic granules or SLs which transport the complete set of effector molecules to the cytotoxic IS, several lines of evidence challenge this generalized assumption. Earlier reports already indicated a differential regulation of cytotoxic effector mechanisms. For example, it was suggested that the depletion of extracellular Ca 2+ does not completely abrogate CTLmediated killing (34, 35) , but-as was found later-rather results in an exclusive and rapid mobilization of only prestored FasL from intracellular storage granules (11, (19) (20) (21) 24) . Also, blocking of the CD8 co-receptor in a CD8 + T-cell clone substantially decreased TCR signaling as evidenced by diminished ζ-chain and ZAP70 phosphorylation and calcium mobilization and consequently prevented perforin-dependent killing and IFN-γ production. Since FasL-mediated cytotoxicity remained functional, these results were indicative of a differential (e.g. lower) signaling threshold being required to elicit FasL surface expression (36) . Regarding the molecules that regulate transport and lysosomal trafficking, CLs from ashen mice, that suffer from a mutation of Rab27a and represent a ) and ionomycin (500 ng ml mouse model for Griscelli's syndrome type 2, are characterized by a defect in cytotoxicity towards Fas-negative target cells and in secretion of β-hexosaminidase as a marker for granule exocytosis. At the same time, FasL-mediated killing does not seem to be impaired in ashen mice (37). Last but not least, we have provided substantial evidence for the existence of different forms of lysosome-related effector vesicles in human T and NK cells based on biochemical, proteomic and morphological criteria (17, 18, 27) .
In the present study, we indeed demonstrate different requirements and kinetics for the activation-induced surface expression of FasL, for lysosomal degranulation markers such as CD107a and CD63, and for the release of granzyme B. This strongly supports our hypothesis that characteristic cytotoxicity-associated proteins are stored in different lysosome-related secretory granules that can be mobilized individually by employing different signaling and cytoskeletal pathways.
We previously showed that the phorbol ester/calcium ionophore-induced FasL surface expression follows a biphasic expression pattern. The first maximum after only 10 min relies on the mobilization of preformed FasL molecules from intracellular stores. A second phase of FasL surface expression with a maximum after 90-120 min relies on de novo protein synthesis (24) . Now we report that the early phase of FasL surface appearance is calcium-independent and can thus be triggered by phorbol ester alone, whereas the late phase clearly depends on the presence of extracellular Ca 2+ . In contrast to FasL, however, phorbol ester alone fails to induce the surface expression of CD107a and CD63, whereas both molecules are mobilized upon ionomycin-only treatment. Follow-up experiments with EGTA revealed that the mobilization of both CD107a and CD63 strictly depend on extracellular Ca 2+ ions. Notably, our results and conclusions are in line with the detailed analyses of FasL mobilization in murine T cells. He and Ostergaard showed that the co-culture of murine cytotoxic T cells with target cells induces two phases of FasL cell surface expression with a first calcium-independent phase of expression after 15 min and a second calcium-dependent phase after 120 min. In their hands, plate-bound anti-CD3 antibodies induced the Ca 2+ -dependent mobilization of both CD107a and FasL, whereas cross-linked soluble anti-CD3 mab only induced calcium-independent FasL mobilization but neither CD107a nor calcium-dependent FasL surface expression, once more highlighting that signal requirements for mobilization clearly differ (20) . Along this line, experiments employing the membrane permeant intracellular Ca 2+ chelator BAPTA-AM revealed that Ca 2+ flux from intracellular stores is required and sufficient for the mobilization of prestored FasL, whereas both intracellular 
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and extracellular sources are required for de novo FasL synthesis (19) . Furthermore, experiments employing OT-1 CD8 + T cells revealed that stored FasL is already mobilized at lower peptide concentrations compared to newly synthesized FasL (19) . Moreover, Kassahn et al. showed that the stimulation of both murine and human T-cell blasts with phorbol ester associated with PKC signaling suffices to induce the capacity for the FasL-mediated elimination of target cells. Also in their hands, the surface expression of CD63 and CD107a was only induced in the presence of both phorbol ester and calcium ionophore (21) . However, the kinetics of FasL surface expression were addressed in Jurkat cells transiently transfected with FasL. Nevertheless, and in line with our results, overexpressed FasL was rapidly mobilized within the first 30 min of stimulation with phorbol ester or the combination of phorbol ester and calcium ionophore, but not with ionomycin alone (21) . We also showed that the signal requirements for the granzyme B release resemble those for the mobilization of CD107a and CD63 and Ca 2+ chelation with EGTA confirmed that the granzyme B mobilization is strictly Ca 2+ -dependent. Nevertheless, we repeatedly observed some granzyme B release following treatment with phorbol ester alone and this release could not be blocked by EGTA and was not accompanied by CD107a or CD63 surface expression. Although this release might result from activation-induced T-cell death mediated by TPA-induced FasL surface expression, this observation definitely requires further investigation.
In conclusion, our findings clearly indicate that preformed FasL is stored in secretory granules different from the classical cytotoxic granules containing the major portion of granzyme B and perforin and for which degranulation correlates with CD107a/CD63 surface expression. By using imaging cytometry we could verify that endogenous FasL and CD107a segregate to different intracellular granules, whereas CD63, granzyme B and perforin colocalize with CD107a. This confirmed earlier observations from overexpression systems or murine T cells that were, however, only derived from microscopical inspection of individual cells (20, 21) . Most importantly, the signal requirements for the mobilization of preformed FasL differ from those required to elicit classical degranulation. Our density gradient centrifugation of enriched organelles, however, revealed that FasL, CD107a and CD63 segregate to the same fraction, suggesting storage in a common less electron-dense granule type, whereas granzyme B segregated to the dense fraction which was almost devoid of both CD107a and CD63 (17, 18, 27) . Of note in this context, a careful inspection of the electron micrographs obtained from the individual fractions revealed that the granules derived from the FasL-positive fraction 2 differ in the overall size (ranging from 200 to 750 nm) and also display slight differences in electron density. This might indicate that this fraction might contain a more heterogeneous population of lysosomal vesicles that differ in the abundance of marker and effector proteins. In contrast, the granzyme B-positive fraction 6 contained more uniformly shaped electron-dense particles of about 200-300 nm in size (18, 27) .
Initially, human T-cell SLs have been described as membrane-surrounded multivesicular structures of about 700 nm in diameter that contain one or more electron-dense cores with a diameter of about 300 nm that are also membrane-enclosed (38) . Interestingly, CD107a was predominantly located in the outer membrane and only occasionally associated with internal vesicles or the membrane of the electron-dense cores. In contrast, granzyme B was exclusively located in the electron-dense structures. Thus, these electron-dense cores might well represent the structures that we enriched in the granzyme B-positive but CD107a-and CD63-negative fraction 6 (18, 27) . However, the activation-induced release of these electron-dense structures and associated granzyme would be preceded by the fusion of the CD107a-positive outer membrane of the multivesicular effector compartment and thus explain the observed functional connection of CD107a and granzyme B mobilization.
We also reported previously that activation-induced surface expression of FasL is actin-dependent and blocked by respective inhibitors including Latrunculin A or Cytochalasin D (24) and that the proteomic profiling of FasL-positive granules revealed an association with adapter proteins such as Nck or WASp, which have been functionally associated with the regulation of actin dynamics, and cytoskeletal proteins including β-actin, alpha-actinin 4 and coronin 1A. In contrast, granzyme B storage granules associated with different cytoskeletal elements including for example the actin motor protein myosin 2a (17, 18) . Functionally, the transport of FasL + granules to the cytotoxic IS proved to be dependent on the molecular interaction of FasL with Nck (39) .
We now show that, while Latrunculin A inhibits the mobilization of FasL, the mobilization of CD107a, CD63 and granzyme B is rather facilitated. Although the inhibitor already induces an increase in CD107a surface expression in unstimulated cells, the positive modulatory effect on the activation-induced mobilization process is much more pronounced. Furthermore, we also show that the myosin 2a inhibitor Blebbistatin increases FasL expression but impedes CD107a and CD63 mobilization. Again, the increase in FasL surface expression is already evident in unstimulated cells. In sum, the inhibitor studies strongly support our hypothesis that distinct populations of effector granules are differentially associated with cytoskeletal elements thus allowing for distinct transport routes for activation-induced mobilization that depend on different cytoskeletal regulators.
We are fully aware, however, that the exact molecular processes and mechanisms that govern granule mobilization and activation-induced surface expression of FasL and CD107a/ CD63 and the secretion of granzyme B still remain elusive. In this context, it was thought that the filamentous F-actin network in secretory cells might act as a barrier to prevent permanent exocytosis and that the loss of cortical F-actin facilitates secretion (40) . On the other hand, however, it was suggested that in certain cells, F-actin might actively facilitate secretion, which would be in line with the observed inhibition of secretion in the presence of actin inhibitors. As an example, in mast cells (that also carry 'secretory lysosomes' for the storage and transport of serotonin and histamine), F-actin is required for agonistinduced secretion (41) , whereas the cortical F-actin net in neutrophils constitutes a barrier for granule secretion (42) .
For cytotoxic T lymphocytes, it was reported that actin is cleared from the central region of the IS. The microtubuleorganizing center translocates to the IS and granules are transported towards the intercellular contact site along microtubules by dynein to ultimately fuse with the plasma membrane (43) . In the case of NK cells, however, high-resolution imaging revealed that the central region of the synapse is not completely devoid of F-actin, but displays granule-sized actin hypodensities (44) . Interestingly, in NK cells, the actin motor protein myosin 2a proved to be necessary for granule exocytosis (33) . Functionally, myosin 2a associates with lytic granules and enables their interaction with F-actin. Thus, the motor function of myosin 2a might in fact govern granule motility in the actin network as a prerequisite for degranulation (45) .
We showed that, in contrast to FasL, a de novo synthesis of CD107a and CD63 seems to play a minor role indicating that the increasing surface expression relies on the slow and constant transport of CD107 + and CD63 + granules to the cell membrane. In the presence of CHX, CD63 and especially CD107a surface levels are further increased implying that stimulation might induce the gene expression of a negative regulator of CD107 surface expression. Of note, CHX has been implicated in the inhibition of lysosomal proteolysis possibly by abrogating the synthesis of a rapidly turning over protein involved in the degradation of proteins (46) . However, detailed mechanisms for the regulation of activation-induced CD107a surface expression are not described. This is even more surprising and unsatisfactory because CD107a translocation is not only routinely used to determine cytotoxic effector function of CLs, but CD107a is also required for the self-protection of cytotoxic NK cells during degranulation (47) . In contrast to CD107a and CD63, the release of granzyme B into the culture supernatant was almost completely blocked by CHX and therefore presumably relied on a preceding de novo protein synthesis. However, using laser scanning microscopy (not shown) and also applying imaging flow cytometry, we and others clearly detected granule-associated granzyme B in untreated cells. In addition, we observed a rapid activation-induced release of granzyme B in the presence of Latrunculin A. One possible explanation for this discrepancy might be that the load of granzyme B which is initially released from intracellular stores upon TPA/ionomycin treatment is below the detection limit of the applied ELISA, whereas the bulk of newly synthesized granzyme B might exceed the amount of prestored effector molecules.
Regarding cytotoxic effector function, it has been suggested that FasL released from intracellular granules plays an important role for the specific elimination of conjugated target cells, whereas newly synthesized FasL predominantly mediates bystander killing (19) . Since a low activation threshold triggers the release of preformed FasL, specific FasL-mediated killing might thus predominate at low antigen doses. Furthermore, stored FasL is rapidly removed from the cell surface, possibly to prevent collateral damage. Although ADAM proteases are clearly involved in the regulation of FasL surface expression (48, 49) , they presumably do not mediate this more or less complete down-regulation (24) . Since the association with membrane microdomains modulates the death-inducing capacity of FasL (50) and might also influence its susceptibility to shedding (51) , it might be of interest to investigate whether stored and newly synthesized FasL molecules differ with respect to their lipid environment. Of note, it has been shown before that TCR ligation also triggers de novo synthesis of granzymes and perforin to replenish the granules. However, in this situation, considerable amounts of effectors are secreted or exocytosed via a non-granule pathway and thus contribute to bystander killing (52) .
Similar to what we and others suggest for cytotoxic effector molecules, Huse et al. showed that T cells also employ two distinct pathways for the release of cytokines and chemokines. Whereas some of these molecules are targeted to the IS to assure a local antigen-specific and cell-cell-contact-mediated effect, others are delivered in a multidirectional way to affect cells systemically also at distant sites. As an example, prestored Rantes (CCL5) is delivered to the IS, but newly synthesized molecules are transported to the cell membrane in a multidirectional fashion (53) .
In conclusion, our findings clearly support that stored cytotoxic effector molecules not only differ in function, but also employ different routes for their mobilization and release. This apparent versatility of cytotoxic effector granules might be regulated in a context-dependent manner and thus allow for a more selective and effective killing of infected or tumor cells. We believe that the ongoing analysis of surface receptors and additional factors that govern the fine-tuning of the cytotoxic response might help to unravel this new level of regulation. The increasing knowledge might not only be important to further develop current concepts of directional immunotherapy but also to define and possibly harness residual cytotoxic activity for example in pediatric immunodeficiencies associated with lysosomal storage or transport diseases.
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